A*STAR Infectious Diseases Labs (A*STAR IDL)

Research suggests monitoring individuals previously infected with Zika virus for chronic skin diseases caused by overactive T cells.

While the new Omicron XBB COVID-19 subvariant deftly dodges immune defences even in vaccinated individuals, researchers find that mixed mRNA vaccines may offer a vital boost of protection.

A study reveals how age, SARS-CoV-2 variants and booster shots affect immune responses to the COVID-19 vaccine.

Scientists survey how the mpox virus spreads through populations, the immunology of infections and current treatment interventions.

A novel tissue-profiling approach provides new insights into the mechanisms of fatal COVID-19 by analysing
different molecules and cell populations within organs.

Inactivated COVID-19 vaccines could be an equally potent alternative for people with allergic sensitivities to mRNA-based vaccines.

An analysis of cellular immune responses reveals that mixing COVID-19 vaccines and boosters may offer enhanced protection for at-risk populations.

Leveraging on its public sector and industry collaborations, A*STAR and the Experimental Drug Development Centre hold the keys to effective drug discovery and development.

Drug-resistant malarial parasites form flower-like structures to shield themselves from attack by antimalarial drugs and the immune system.

In 2023, the National Research Foundation Singapore selected 10 A*STAR researchers to be a part of its competitive Investigatorship and Fellowship grant programmes.

A profile of the immune responses from Singaporean patients recovered from COVID-19 has revealed an urgent need to update vaccines against new viral variants.

Remdesivir treatment is more likely to be successful in COVID-19 patients who are naturally able to mount a strong immune response against infections.